冷冻消融治疗结直肠癌外周肺转移瘤:一项双中心回顾性研究
这项双中心回顾性研究纳入73例结直肠癌外周肺转移患者(113个转移灶、89次手术),评估冷冻消融的肿瘤学疗效与并发症;
要点
- 外周肺转移灶冷冻消融技术成功率高,局部控制率1年95%、2至4年89%。
- 按转移灶局部复发率7%(8/113),中位复发时间19个月,其中7例伴远处复发。
- 远处进展见于56.2%(41/73)患者,与肝转移史及同时性肺转移显著相关(p<0.05)。
核心结论
- 冷冻消融对外周肺转移的结直肠癌患者局部控制率高且似乎耐受良好,是一种可行的治疗选择,可使患者获得较长的无化疗间期。
研究设计与样本
- 双中心回顾性研究,纳入2017年1月至2022年6月接受冷冻消融、经组织学确诊结直肠癌且影像学确认外周肺转移(距肋胸膜、膈胸膜或颈胸膜≤2 cm)的患者73例(中位年龄69岁,范围47.0-83.0;男性38例,52.0%),共113个转移灶、89次手术;排除肺实质内转移、靠近纵隔胸膜者及无随访者。
诊断标准与关键数值
- 按转移灶局部复发8/113(7%),见于7例患者,中位复发时间19个月,其中7例伴远处复发。
- 局部无进展生存率1年95%,2年、3年及4年均为89%。
- 远处进展41/73(56.2%),与肝转移史及同时性肺转移显著相关(p<0.05)。
- 中位无化疗生存14个月(IQR 5.0-21.5)。
临床应用与阅片要点
- 外周肺转移灶(距胸膜≤2 cm)行冷冻消融技术成功率高,可作为局部控制的可选手段。
- 随访中需关注局部复发(中位19个月)及远处进展,尤其有肝转移史或同时性肺转移者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To evaluate the oncological efficacy and complications of cryoablation (CA) in treating lung metastases from colorectal cancer (CRC) at the lung periphery.
MATERIALS AND METHODS: The inclusion criteria for this bicenter retrospective study included patients with histologically confirmed CRC, with radiologically confirmed lung metastases at the periphery of the lung (distance of less than or equal to 2 cm from the costal, diaphragmatic, or cervical pleura) treated with CA between January 2017 and June 2022. Patients with intra-parenchymal metastases or metastases close to the mediastinal pleura and patients without follow-up were excluded.
RESULTS: Seventy-three patients were included (median age: 69 years, range 47.0-83.0; 38 males, 52.0%) with 113 metastases and 89 procedures. Technical success was achieved in all procedures. During follow-up (median 22 months), on a per metastasis basis, local recurrence occurred for 8/113 (7%) of the metastases in 7 patients at a median time of 19 months; 7 had concomitant distant recurrence. Local progression-free survival rates were 95% at 1 year and 89% at 2, 3, and 4 years. Distant progression occurred in 41/73 (56.2%) patients, significantly associated with a history of liver metastasis and synchronous lung metastasis (p < 0.05). The median chemotherapy-free survival was 14 (IQR (5.0-21.5)) months. Complications were predominantly mild or moderate, with a low incidence of severe complications.
CONCLUSION: CA demonstrates high rate of local control and appears well-tolerated in the treatment of peripheral lung metastases from CRC. The procedure offers a viable therapeutic option, allowing patients a significant period without chemotherapy.
KEY POINTS: Question Despite its advantages over surgery, data on cryoablation of metastases from colorectal cancer at the periphery of the lung are lacking. Findings Cryoablation enabled very good local control, with local progression-free survival rates of 95% at 1 year and 89% at 2, 3, and 4 years. Clinical relevance Cryoablation is an effective treatment for local tumor control of lung metastases from colorectal cancer at the periphery of the lung. The treatment is well tolerated and can provide patients with substantial relief from chemotherapy.
引用
- Izaaryene J, Grange R, Habouzit V, et al. Cryoablation for treatment of peripheral lung metastases from colorectal cancer: a bicenter retrospective study. Eur Radiol. 2024. PMID: 39572449. doi:10.1007/s00330-024-11153-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。